Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1117304

Quinuclidine-Based Carbamates as Potential CNS Active Compounds


Matošević, Ana; Radman Kastelic, Andreja; Mikelić, Ana; Zandona, Antonio; Katalinić, Maja; Primožič, Ines; Bosak, Anita; Hrenar, Tomica
Quinuclidine-Based Carbamates as Potential CNS Active Compounds // Pharmaceutics, 13 (2021), 3; 420, 15 doi:10.3390/pharmaceutics13030420 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1117304 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Quinuclidine-Based Carbamates as Potential CNS Active Compounds

Autori
Matošević, Ana ; Radman Kastelic, Andreja ; Mikelić, Ana ; Zandona, Antonio ; Katalinić, Maja ; Primožič, Ines ; Bosak, Anita ; Hrenar, Tomica

Izvornik
Pharmaceutics (1999-4923) 13 (2021), 3; 420, 15

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Alzheimer’s disease ; acetylcholinesterase ; butyrylcholinesterase ; inhibition ; covalent binding ; cytotoxicity

Sažetak
The treatment of central nervous system (CNS) diseases related to the decrease of neurotransmitter acetylcholine in neurons is based on compounds that prevent or disrupt the action of acetylcholinesterase and butyrylcholinesterase. A series of thirteen quinuclidine carbamates were designed using quinuclidine as the structural base and a carbamate group to ensure the covalent binding to the cholinesterase, which were synthesized and tested as potential human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. The synthesized compounds differed in the substituents on the amino and carbamoyl parts of the molecule. All of the prepared carbamates displayed a time-dependent inhibition with overall inhibition rate constants in the 103 M−1 min−1 range. None of the compounds showed pronounced selectivity for any of the cholinesterases. The in silico determined ability of compounds to cross the blood–brain barrier (BBB) revealed that six compounds should be able to pass the BBB by passive transport. In addition, the compounds did not show toxicity toward cells that represented the main models of individual organs. By machine learning, the most optimal regression models for the prediction of bioactivity were established and validated. Models for AChE and BChE described 89 and 90% of the total variations among the data, respectively. These models facilitated the prediction and design of new and more potent inhibitors. Altogether, our study confirmed that quinuclidinium carbamates are promising candidates for further development as CNS-active drugs, particularly for Alzheimer’s disease treatment.

Izvorni jezik
Engleski

Znanstvena područja
Kemija, Biologija, Farmacija



POVEZANOST RADA


Projekti:
HRZZ-IP-2016-06-3775 - Aktivnošću i in silico usmjeren dizajn malih bioaktivnih molekula (ADESIRE) (Hrenar, Tomica, HRZZ - 2016-06) ( POIROT)
HRZZ-IP-2020-02-9343 - Razvoj bioaktivnih molekula za tretman neurodegenerativnih bolesti (BioMol4ND) (Bosak, Anita, HRZZ - 2020-02) ( POIROT)
UIP-2017-05-7260 - MOLEKULARNI MEHANIZMI TOKSIČNOSTI PROTUOTROVA I POTENCIJALNIH LIJEKOVA (CellToxTargets) (Katalinić, Maja, HRZZ - 2017-05) ( POIROT)

Ustanove:
Institut za medicinska istraživanja i medicinu rada, Zagreb,
Prirodoslovno-matematički fakultet, Zagreb

Citiraj ovu publikaciju

Matošević, Ana; Radman Kastelic, Andreja; Mikelić, Ana; Zandona, Antonio; Katalinić, Maja; Primožič, Ines; Bosak, Anita; Hrenar, Tomica
Quinuclidine-Based Carbamates as Potential CNS Active Compounds // Pharmaceutics, 13 (2021), 3; 420, 15 doi:10.3390/pharmaceutics13030420 (međunarodna recenzija, članak, znanstveni)
Matošević, A., Radman Kastelic, A., Mikelić, A., Zandona, A., Katalinić, M., Primožič, I., Bosak, A. & Hrenar, T. (2021) Quinuclidine-Based Carbamates as Potential CNS Active Compounds. Pharmaceutics, 13 (3), 420, 15 doi:10.3390/pharmaceutics13030420.
@article{article, year = {2021}, pages = {15}, DOI = {10.3390/pharmaceutics13030420}, chapter = {420}, keywords = {Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, inhibition, covalent binding, cytotoxicity}, journal = {Pharmaceutics}, doi = {10.3390/pharmaceutics13030420}, volume = {13}, number = {3}, issn = {1999-4923}, title = {Quinuclidine-Based Carbamates as Potential CNS Active Compounds}, keyword = {Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, inhibition, covalent binding, cytotoxicity}, chapternumber = {420} }
@article{article, year = {2021}, pages = {15}, DOI = {10.3390/pharmaceutics13030420}, chapter = {420}, keywords = {Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, inhibition, covalent binding, cytotoxicity}, journal = {Pharmaceutics}, doi = {10.3390/pharmaceutics13030420}, volume = {13}, number = {3}, issn = {1999-4923}, title = {Quinuclidine-Based Carbamates as Potential CNS Active Compounds}, keyword = {Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, inhibition, covalent binding, cytotoxicity}, chapternumber = {420} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font